IT1299583B1 - Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica - Google Patents

Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica

Info

Publication number
IT1299583B1
IT1299583B1 IT98MI001094A ITMI981094A IT1299583B1 IT 1299583 B1 IT1299583 B1 IT 1299583B1 IT 98MI001094 A IT98MI001094 A IT 98MI001094A IT MI981094 A ITMI981094 A IT MI981094A IT 1299583 B1 IT1299583 B1 IT 1299583B1
Authority
IT
Italy
Prior art keywords
hmg
protein
medications
preparation
cytotoxic activity
Prior art date
Application number
IT98MI001094A
Other languages
English (en)
Inventor
Alberto Bartorelli
Original Assignee
Vander Way Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IT98MI001094A priority Critical patent/IT1299583B1/it
Application filed by Vander Way Limited filed Critical Vander Way Limited
Priority to PT99926330T priority patent/PT1079849E/pt
Priority to AU43631/99A priority patent/AU4363199A/en
Priority to JP2000549273A priority patent/JP2002515445A/ja
Priority to ES99926330T priority patent/ES2171086T3/es
Priority to EP99926330A priority patent/EP1079849B1/en
Priority to DE69900756T priority patent/DE69900756T2/de
Priority to DK99926330T priority patent/DK1079849T3/da
Priority to AT99926330T priority patent/ATE211391T1/de
Priority to PCT/EP1999/003431 priority patent/WO1999059609A2/en
Publication of ITMI981094A1 publication Critical patent/ITMI981094A1/it
Application granted granted Critical
Publication of IT1299583B1 publication Critical patent/IT1299583B1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IT98MI001094A 1998-05-19 1998-05-19 Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica IT1299583B1 (it)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IT98MI001094A IT1299583B1 (it) 1998-05-19 1998-05-19 Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
AU43631/99A AU4363199A (en) 1998-05-19 1999-05-19 Use of hmg proteins for the preparation of medicaments having cytotoxic activity
JP2000549273A JP2002515445A (ja) 1998-05-19 1999-05-19 細胞毒性活性を有する医薬品調製のためのｈｍｇ蛋白質の使用
ES99926330T ES2171086T3 (es) 1998-05-19 1999-05-19 Uso de proteinas hmg para la preparacion de medicamentos con actividad citotoxica.
PT99926330T PT1079849E (pt) 1998-05-19 1999-05-19 Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica
EP99926330A EP1079849B1 (en) 1998-05-19 1999-05-19 Use of hmg proteins for the preparation of medicaments having cytotoxic activity
DE69900756T DE69900756T2 (de) 1998-05-19 1999-05-19 Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
DK99926330T DK1079849T3 (da) 1998-05-19 1999-05-19 Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
AT99926330T ATE211391T1 (de) 1998-05-19 1999-05-19 Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
PCT/EP1999/003431 WO1999059609A2 (en) 1998-05-19 1999-05-19 Use of hmg proteins for the preparation of medicaments having cytotoxic activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT98MI001094A IT1299583B1 (it) 1998-05-19 1998-05-19 Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica

Publications (2)

Publication Number Publication Date
ITMI981094A1 ITMI981094A1 (it) 1999-11-19
IT1299583B1 true IT1299583B1 (it) 2000-03-16

Family

ID=11380053

Family Applications (1)

Application Number Title Priority Date Filing Date
IT98MI001094A IT1299583B1 (it) 1998-05-19 1998-05-19 Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica

Country Status (10)

Country Link
EP (1) EP1079849B1 (it)
JP (1) JP2002515445A (it)
AT (1) ATE211391T1 (it)
AU (1) AU4363199A (it)
DE (1) DE69900756T2 (it)
DK (1) DK1079849T3 (it)
ES (1) ES2171086T3 (it)
IT (1) IT1299583B1 (it)
PT (1) PT1079849E (it)
WO (1) WO1999059609A2 (it)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US20020164644A1 (en) * 2000-04-05 2002-11-07 Ikuro Maruyama Adsorbents for high mobility group proteins and column for purifying body fluid
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
CA2470640A1 (en) * 2001-12-19 2003-06-26 Alcedo Biotech Gmbh Use of hmgb proteins and nucleic acids that code therefor
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
EP1668035A2 (en) 2003-09-11 2006-06-14 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
CN101132811B (zh) 2004-10-22 2012-05-30 米迪缪尼有限公司 抗hmgb1的高亲和力抗体及其用法
CA2631212A1 (en) 2005-11-28 2007-07-05 Medimmune, Llc Antagonists of hmgb1 and/or rage and methods of use thereof
NO2525817T3 (it) 2010-01-21 2018-01-06
BR112012031211A2 (pt) 2010-06-09 2018-01-30 Univ Arkansas métodos e vacina para reduzir a infecção causada pelo campylobacter
EP2956165B1 (en) 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
CN105142653B (zh) 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62166897A (ja) * 1986-01-20 1987-07-23 Toyo Soda Mfg Co Ltd 核内非ヒストン蛋白質に対するモノクロ−ナル抗体
EP0727487A1 (en) * 1995-02-17 1996-08-21 K.U. Leuven Research & Development Multiple-tumor aberrant growth genes
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
JP3018313B2 (ja) * 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤

Also Published As

Publication number Publication date
AU4363199A (en) 1999-12-06
PT1079849E (pt) 2002-06-28
EP1079849A2 (en) 2001-03-07
ES2171086T3 (es) 2002-08-16
WO1999059609A2 (en) 1999-11-25
WO1999059609A3 (en) 2000-01-27
ITMI981094A1 (it) 1999-11-19
DE69900756D1 (de) 2002-02-28
DK1079849T3 (da) 2002-04-22
EP1079849B1 (en) 2002-01-02
ATE211391T1 (de) 2002-01-15
JP2002515445A (ja) 2002-05-28
DE69900756T2 (de) 2003-03-13

Similar Documents

Publication Publication Date Title
ATE254630T1 (de) Cyclosporine
PT1079849E (pt) Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
BR9713404A (pt) ésteres de n-(aril/heteroarilacetil) aminoácidos, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da liberação de peptìdeo beta-amilóide e/ou de sua sìntese por uso de tais compostos.
HUP0004310A3 (en) Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
CA2280875A1 (en) Remedies for lymphocytic tumors
ATE155486T1 (de) Zyklische peptide und ihre verwendung
AU2845599A (en) Pharmaceutical compositions and their use
BR9810495A (pt) Composição farmacêutica
DZ2509A1 (fr) Analogues peptidiques de la lh-rh leur utilisationet les compositions pharmaceutiques les contenant.
WO1999060013A3 (en) Il-6 antagonist peptides
RU93004445A (ru) Новые 2-циано 3-гидроксиенамидные производные, способ их получения, их применение в качестве медикаментов, содержащие их фармацевтические композиции и новые полученные промежуточные продукты
AU589939B2 (en) Medical composition for injection containing a spergualin as active ingredient and process for preparing the same
CA2287534A1 (en) Biodegradable microparticles for the sustained delivery of therapeutic drugs
IT1270618B (it) Proteine ad attivita' antitumorale
BR9810433A (pt) Composições anti-helmìnticas
NZ331083A (en) Pharmaceutical preparations of cilansetron stabilized against racemization
AU3739500A (en) Protease resistant flint analogs
RU94040865A (ru) Производные пептида и их терапевтически приемлемые соли, способ их получения, фармацевтическая и косметическая композиция с антивирусной активностью
BR0011845A (pt) Complexo farmacêutico
EP1132383A4 (en) NEW AGAROFURAN DERIVATIVES, THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE AS MEDICINE
IT1216104B (it) Peptidi ad attivita' farmaceutica.
IT1277391B1 (it) Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
FR2766489B1 (fr) Derives de streptogramines, leur preparation et les compositions qui les contiennent
PL355852A1 (en) Fragments of virus protein vp2 or 3 of the polyoma virus, used for transporting active ingredients

Legal Events

Date Code Title Description
0001 Granted